Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report
- 7 January 2005
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (1) , 61-72
- https://doi.org/10.1002/art.20764
Abstract
Objective Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF) antagonists is highly effective, but their mechanisms of action are not completely clear. Since anti‐TNF therapy induces a decrease in synovial cellularity, this study focused on the modulation of RA synovial apoptosis following treatment with either soluble TNF receptor (etanercept) or TNF chimeric monoclonal antibody (infliximab). Methods Apoptosis (TUNEL and active caspase 3 staining) and cell surface markers were evaluated by immunohistochemistry in synovial biopsy samples obtained before and after 8 weeks of treatment with etanercept (12 patients) or infliximab (9 patients). We also determined by flow cytometry the in vitro effect of etanercept and infliximab on apoptosis of RA mononuclear cells derived from the synovial fluid (SF) and peripheral blood (PB). Results Eight weeks of treatment with etanercept and with infliximab significantly increased synovial apoptosis. This change was accompanied by a significant decrease in the synovial monocyte/macrophage population. The decrease in lymphocyte numbers did not reach statistical significance. In vitro, 24 hours of incubation with either etanercept or infliximab induced apoptosis of the SF monocyte/macrophage population. PB monocyte/macrophages were less susceptible to anti‐TNF–mediated apoptosis. No changes in the rate of apoptosis were observed in the lymphocyte population derived from either SF or PB. Conclusion In RA patients, both etanercept and infliximab are able to induce cell type–specific apoptosis in the monocyte/macrophage population. This suggests a potential pathway that would account for the diminished synovial inflammation and the decreased numbers of synovial macrophages evident after TNF blockade.Keywords
This publication has 43 references indexed in Scilit:
- Accumulation of plasma nucleosomes upon treatment with anti‐tumour necrosis factor‐α antibodiesJournal of Internal Medicine, 2004
- Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's diseaseGut, 2004
- The immunological and genetic basis of inflammatory bowel diseaseNature Reviews Immunology, 2003
- Tumor Necrosis Factor (TNF)–α–Induced Interleukin‐8 in Human Blood Cultures Discriminates Neutralization by the p55 and p75 TNF Soluble ReceptorsThe Journal of Infectious Diseases, 2000
- The Role of TNFα and IL-1 in Rheumatoid ArthritisPublished by S. Karger AG ,2000
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.Journal of Clinical Investigation, 1994
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988